noninvasive brain stimulation in neurorehabilitation roy hamilton, md, ms assistant professor of...
TRANSCRIPT
![Page 1: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/1.jpg)
Noninvasive brain stimulation in neurorehabilitation
Roy Hamilton, MD, MSAssistant Professor of Neurology &Physical Medicine & RehabilitationDirector, Laboratory for Cognition &Neural StimulationUniversity of Pennsylvania
Disclosures• Medical consultant for
Neuronix, LTD, Israel• Funding from NIH/NINDS,
NIH/NIDCD, RWJF, Dana Foundation
![Page 2: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/2.jpg)
NIBS in post-stroke neurorehabilitation
Paresis
VisuospatialNeglect
Aphasia
Post-Stroke Motor & Cognitive Deficits• Common and debilitating• Current therapies: Ineffective (at
typical doses)• Recovery depends on network
reorganization
![Page 3: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/3.jpg)
NIBS in cognitive neurorehabilitation:a model system in translational cognitive neuroscience
Poeppel D., Current Opinions in Neurobiology, 2014
How do intact cognitive systems systems work?
How do injured systems differ from normal systems?
*
Can we facilitate reorganization of injured neural systems?
Normal Systems
Turkeltaub et al. Neurology, 2011
Reorganized Systems
Does it work?
Hypothesis-guidedNeuromodulation
Cognitive Outcomes
![Page 4: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/4.jpg)
Interhemispheric Inhibition Model
(-) (-)
Inhibit Excite
• Low-frequency rTMS• Cathodal tDCS
• High-frequency rTMS• Anodal tDCS
“All models are wrong, but some are useful”-George E.P. Box
Adapted from Hamilton et al., 2011
![Page 5: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/5.jpg)
TMS Studies in Post-stroke Paresis
Hsu et al., Stroke, 2012
Effect size (All studies): 0.55; 95% CI (0.37-0.72)Effect size (Contralesional rTMS): 0.69; 95% CI (0.42-0.95)
![Page 6: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/6.jpg)
Contrastim and NICHE
Harvey et al., 2014, AHA/ASA International Stroke Conference
• Contralesional rTMS + OT vs sham +OT
• 20 rTMS/10 Sham• 18 sessions/6 weeks• 1 week, 1 month, 6
month follow-up
• 80% Clinically meaningful response rate
• Navigated Inhibitory rTMS in Contralesional Hemisphere Evaluation (NICHE)• Phase III trial• 2 years• 12 sites
![Page 7: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/7.jpg)
rTMS in Aphasia
Ren et al., PLOS One, 2014
Garcia et al., JoVE, 2013
![Page 8: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/8.jpg)
tDCS in Aphasia: Promising But Preliminary
Monti et al., JNNP, 2013
L R
• Small samples• Clinical Heterogeneity
-Aphasia type-Chronicity
• Variable Parameters• Limited Follow-up• Promising studies
ongoing (e.g. Fridriksson)
Multiple Mechanisms of Aphasia RecoveryAdapted from Torres et al., 2013
![Page 9: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/9.jpg)
Koch et al., 2012
• Randomized, double-blind, sham-controlled
• 10 sessions cTBS over 2 weeks • Intact left parietal cortex• 2 week & 4 week follow-up
(post-initiation of therapy)• 18 subacute ischemic stroke • Behavioral Inattention Test • Bifocal TMS to assess fronto-
parietal excitability
Behavioral Inhibition TestPPC-M1 Excitability
![Page 10: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/10.jpg)
tDCS Enhances Spatial Processing
Medina et al., 2012
EgocentricNeglect
AllocentricNeglect
![Page 11: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/11.jpg)
Challenges to NIBS in Rehab• No FDA-approved rehab indications to date• Much research at proof-of-concept stage
•Phase I: •Dose-effect relationships•Testing of potentially risky populations
•Phase II/III: •Recruitment/eligibility challenges•Heterogeneous patient populations•Multiple sessions & attrition
•Phase III: •Control group and blinding issues•Heterogeneity of approaches•Small sample sizes/single sites
FDA Clinical Trial Phases:
Phase I: Screening for safety
Phase II: Smaller, controlled trials of efficacy
Phase III: Pivotal larger studies of safety and efficacy*
*Two positive phase III trials are required for FDA approval.
Challenges to clinical development of TMS/tDCS
![Page 12: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/12.jpg)
• TMS as a prognostic indicator of stroke outcomes– Motor tract patency– Marker of plasticity
• TMS pre-surgical mapping of motor function and language
• NIBs to treat motor, cognitive, neuropsychological disorders associated with TBI
Other applications in brain injury
![Page 13: Noninvasive brain stimulation in neurorehabilitation Roy Hamilton, MD, MS Assistant Professor of Neurology & Physical Medicine & Rehabilitation Director,](https://reader030.vdocuments.us/reader030/viewer/2022032703/56649d095503460f949db69a/html5/thumbnails/13.jpg)
Follow us on Twitter @PennMedLCNSLCNS email: [email protected] website: http://www.med.upenn.edu/lcns
FacultyRoy Hamilton, MD, MSH. Branch Coslett, MDSudha Kessler, MD
Research StaffOlufunsho Faseyitan, MSDaniela Sacchetti, MSJuliann Purcell, MScFelix Gervits, MA
Postdoctoral FellowsRachel Wurzman, PhDDenise Harvey, PhDJohn Megdaglia, PhD
Perelman School Of MedicineCatherine NoriseHarrison McAdams
Penn School of NursingDarina Petrovsky, MSN
UndergraduatesJay GillJill SorcherTrevin GlasgowMenvekeh Daramay
Students
CollaboratorsPriyanka Shah-Basak, PhDPeter Turkeltaub, MD, PhD (Georgetown)Jared Medina, PhD (U. Delaware)Margaret Naeser, PhD (Boston University)Alvaro Pascual-Leone, MD, PhD (Harvard)